E. Berge

发表

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

Steinar Lundgren, Stian Knappskog, Lars Fredrik Engebretsen, 2008, PloS one.

CHEK 2 Mutations Affecting Kinase Activity Together With Mutations in TP 53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

P. Lønning, S. Lundgren, S. Knappskog, 2009 .

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

A. Howell, I. Janszky, L. Vatten, 2018, Annals of Internal Medicine.

Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity.

P. Lønning, J. Lillehaug, V. Staalesen, 2010, Biochimica et biophysica acta.

Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo

T. Aas, S. Geisler, P. Lønning, 2015, Molecular oncology.

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

P. Lønning, S. Knappskog, J. Lillehaug, 2013, Biochimica et biophysica acta.

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

P. Lønning, S. Knappskog, G. Jönsson, 2013, Clinical & Experimental Metastasis.

Alterations of the retinoblastoma gene in metastatic breast cancer

P. Lønning, S. Knappskog, J. Lillehaug, 2011, Clinical & Experimental Metastasis.

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers

S. Geisler, P. Lønning, A. Børresen-Dale, 2010, Molecular Cancer.

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

P. Lønning, S. Knappskog, G. Jönsson, 2013, Clinical & Experimental Metastasis.